Clinical Trials

100 enrolled

Recurrence, Lymphoma, B-Cell

NCT06026319 2026-03-16

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

200 enrolled

Lymphoma, B-Cell

NCT05801913 2026-03-05

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

Lymphoma, B-Cell

NCT06173518 2026-03-02

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

30 enrolled

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05432635 2026-02-23

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05389423 2026-02-19

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

25 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT06191887 2026-02-13

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

27 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07398963 2026-02-10

Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma

48 enrolled

Lymphoma, B-Cell

NCT06565689 2026-02-05

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

48 enrolled

Recurrence, Lymphoma, B-Cell

NCT04884035 2026-02-04

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

174 enrolled

Lymphoma, B-Cell

NCT06539338 2026-02-04

INVISE

34 enrolled

Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06528301 2026-01-12

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

106 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT05098613 2025-12-24

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

68 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT06392477 2025-12-23

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma

96 enrolled

Lymphoma, B-Cell

NCT04077307 2025-12-19

MAATEO

LymphoidOther hematologic neoplasmPlasma cell

9 enrolled

Leukemia, Multiple Myeloma, Lymphoma, B-Cell

NCT06544265 2025-12-18

SynKIR-310 for Relapsed/Refractory B-NHL

18 enrolled

LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Pyloric Stenosis, Hypertrophic, Dendritic Cell Sarcoma, Interdigitating

NCT06208735 2025-12-15

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06824701 2025-12-03

TARZAN

Recurrence, Lymphoma, B-Cell

NCT05370430 2025-11-20

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

36 enrolled

Recurrence, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT06707259 2025-11-20

Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL

Lymphoma, B-Cell

NCT07053670 2025-11-17

CT1190B

27 enrolled

Lymphoma, B-Cell

NCT05773040 2025-11-10

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

33 enrolled

Lymphoma, Lymphoma, B-Cell

NCT03017820 2025-10-08

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT05365659 2025-10-01

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

140 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04993690 2025-09-23

A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

200 enrolled

Lymphoma, B-Cell

NCT06792734 2025-09-18

Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

Lymphoma, B-Cell

NCT05934838 2025-08-15

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07093086 2025-07-30

Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma

20 enrolled

Lymphoma, B-Cell

NCT07072169 2025-07-18

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

56 enrolled

Lymphoma, B-Cell

NCT07073833 2025-07-18

The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma

40 enrolled

Lymphoma, B-Cell

NCT04892277 2025-07-01

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

25 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT05412290 2025-04-24

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06879340 2025-04-06

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

54 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT06251180 2025-03-25

Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma

112 enrolled

Lymphoma, B-Cell

NCT06313957 2025-03-25

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

42 enrolled

Lymphoma, B-Cell

NCT04637763 2025-03-24

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

72 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05472558 2025-03-04

Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

48 enrolled

Lymphoma, B-Cell

NCT06820268 2025-03-04

A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

168 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell

NCT06822868 2025-02-12

CT1190B

Lymphoma, B-Cell

NCT04807881 2025-01-22

Phase Ib Clinical Study of Keynatinib

75 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT06758713 2025-01-06

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies

LymphoidOther hematologic neoplasmPlasma cell

60 enrolled

Multiple Myeloma, Lymphoma, B-Cell, Hematologic Neoplasms

NCT06725524 2024-12-10

A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma

186 enrolled

Lymphoma, B-Cell

NCT05476770 2024-12-06

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

54 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hodgkin Disease, Leukemia, Biphenotypic, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05312801 2024-10-21

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

20 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06180174 2023-12-28

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma